Hospital
University Hospitals Ahuja Medical Center, INC
University Hospitals Ahuja Medical Center, INC was paid $21.13M by Medicaid between Jan 2018 and Dec 2024, across 313 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoUNIVERSITY HOSPITALS AHUJA MEDICAL CENTER, INC
BEACHWOOD, OH 44122
BEACHWOOD, OH 44122
33aNPI1609189604assigned 07/19/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.13M
24GClaims626,888
24DCodes billed313
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#52 of 101
Median peer was paid$22.32M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCHILLERO, ANTHONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,663 | $1.86M | |
| 2019 | 43,967 | $1.58M | |
| 2020 | 23,684 | $1.29M | |
| 2021 | 31,487 | $1.51M | |
| 2022 | 40,620 | $1.63M | |
| 2023 | 236,318 | $7.32M | |
| 2024incomplete | 197,149 | $5.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 45,817 | 42,466 | $5.27M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 23,396 | 21,000 | $3.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 17,309 | 14,826 | $1.99M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.6% | 4,768 | 3,693 | $1.19M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 9,413 | 8,640 | $972K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 3,956 | 3,282 | $861K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 7,215 | 6,566 | $747K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 3,115 | 2,503 | $653K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,290 | 1,034 | $314K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 3,291 | 1,673 | $271K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,236 | 1,687 | $268K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.2% | 1,543 | 1,344 | $261K |
301 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 1,183 | $255K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 996 | $230K |
| G0378 | Hospital observation service, per hour | 1.1% | 4,137 | $228K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,126 | $223K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,886 | $194K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,101 | $178K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,358 | $168K |
| 64483 | <1% | 357 | $158K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,555 | $145K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,262 | $130K |
| 80053 | Comprehensive metabolic panel | <1% | 31,240 | $129K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 369 | $123K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 223 | $113K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,077 | $100K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 6,283 | $81K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,953 | $78K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 341 | $78K |
| 76770 | <1% | 568 | $77K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 549 | $75K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 932 | $74K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,583 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,387 | $69K |
| 73030 | <1% | 2,299 | $67K | |
| 20610 | <1% | 617 | $65K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 743 | $64K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,193 | $64K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,332 | $60K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,469 | $59K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 293 | $58K |
| 20611 | <1% | 242 | $51K | |
| 93971 | <1% | 846 | $51K | |
| 76536 | <1% | 520 | $49K | |
| 73610 | <1% | 1,901 | $47K | |
| 73630 | <1% | 1,977 | $47K | |
| 70496 | <1% | 196 | $46K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,228 | $45K |
| 71250 | <1% | 644 | $45K | |
| 82805 | <1% | 1,954 | $45K | |
| 72110 | <1% | 976 | $44K | |
| 73562 | <1% | 1,165 | $40K | |
| 76000 | <1% | 422 | $40K | |
| 73130 | <1% | 1,485 | $39K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 327 | $39K |
| 93970 | <1% | 375 | $38K | |
| 62323 | <1% | 115 | $38K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,554 | $37K |
| 73502 | <1% | 1,254 | $36K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 259 | $35K |
| 73564 | <1% | 1,405 | $35K | |
| 70491 | <1% | 136 | $35K | |
| 84484 | <1% | 13,583 | $31K | |
| 87631 | <1% | 407 | $29K | |
| 97016 | <1% | 866 | $27K | |
| 73560 | <1% | 919 | $27K | |
| 93017 | <1% | 386 | $26K | |
| 97161 | <1% | 670 | $25K | |
| 73110 | <1% | 1,005 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 56 | $23K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 861 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,697 | $21K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 191 | $21K |
| 96367 | <1% | 483 | $21K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 62 | $21K |
| 70486 | <1% | 402 | $21K | |
| 74018 | <1% | 674 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,227 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,264 | $20K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,263 | $18K |
| 86850 | <1% | 1,279 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,235 | $17K |
| 73590 | <1% | 764 | $16K | |
| 73140 | <1% | 444 | $16K | |
| 72050 | <1% | 439 | $16K | |
| 12001 | <1% | 104 | $15K | |
| 72100 | <1% | 471 | $14K | |
| 97165 | <1% | 331 | $13K | |
| 52000 | <1% | 17 | $13K | |
| 85027 | <1% | 5,215 | $13K | |
| 72131 | <1% | 311 | $12K | |
| 86900 | <1% | 1,395 | $12K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 386 | $11K |
| 96376 | <1% | 3,402 | $11K | |
| 72170 | <1% | 495 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,714 | $11K |
| 73552 | <1% | 464 | $11K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,470 | $11K |
| 80320 | <1% | 738 | $11K | |
| 82947 | <1% | 8,721 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,017 | $10K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 20 | $10K |
| 94726 | <1% | 160 | $9K | |
| 72141 | <1% | 55 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 659 | $8K |
| 94729 | <1% | 167 | $8K | |
| 94060 | <1% | 83 | $8K | |
| 71271 | <1% | 53 | $8K | |
| 73090 | <1% | 441 | $8K | |
| 73080 | <1% | 397 | $7K | |
| 83605 | <1% | 6,045 | $7K | |
| 88307 | <1% | 155 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,440 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 73 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,746 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 264 | $7K |
| 93975 | <1% | 63 | $6K | |
| 76642 | <1% | 74 | $6K | |
| 84702 | <1% | 4,971 | $6K | |
| 70498 | <1% | 175 | $6K | |
| 70544 | <1% | 48 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,710 | $5K |
| 72197 | <1% | 28 | $5K | |
| 73221 | <1% | 30 | $5K | |
| 90715 | <1% | 358 | $5K | |
| 81001 | <1% | 11,902 | $5K | |
| 99152 | <1% | 827 | $5K | |
| 87081 | <1% | 1,165 | $5K | |
| J3490 | Unclassified drugs | <1% | 3,289 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,135 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 966 | $4K |
| 86780 | <1% | 265 | $4K | |
| 81003 | <1% | 6,385 | $4K | |
| 73070 | <1% | 165 | $4K | |
| 80076 | <1% | 1,772 | $4K | |
| 76801 | <1% | 315 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 186 | $4K |
| 83735 | <1% | 4,326 | $4K | |
| 73100 | <1% | 94 | $4K | |
| 36430 | <1% | 13 | $3K | |
| 93922 | <1% | 73 | $3K | |
| 93308 | <1% | 13 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 371 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,694 | $3K |
| 81025 | <1% | 8,000 | $3K | |
| 83690 | <1% | 6,188 | $3K | |
| 72040 | <1% | 87 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,115 | $2K |
| 97116 | <1% | 113 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 941 | $2K |
| 10060 | <1% | 18 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 287 | $2K |
| 86140 | <1% | 1,095 | $2K | |
| 83880 | <1% | 2,508 | $2K | |
| 72082 | <1% | 34 | $2K | |
| 87634 | <1% | 887 | $2K | |
| 64447 | <1% | 17 | $2K | |
| 85610 | <1% | 4,523 | $2K | |
| 73060 | <1% | 120 | $2K | |
| 86901 | <1% | 1,396 | $2K | |
| 12011 | <1% | 12 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 503 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,293 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 455 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,876 | $2K |
| 76870 | <1% | 55 | $2K | |
| 80069 | <1% | 382 | $2K | |
| 72128 | <1% | 58 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 446 | $2K |
| 72190 | <1% | 45 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,822 | $2K |
| 29075 | <1% | 14 | $1K | |
| 93246 | <1% | 35 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 870 | $1K |
| 82077 | <1% | 1,139 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,690 | $1K |
| 87800 | <1% | 503 | $1K | |
| 80143 | <1% | 1,495 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 409 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,919 | $1K |
| 82330 | <1% | 1,944 | $1K | |
| 87210 | <1% | 1,056 | $1K | |
| 87040 | <1% | 1,642 | $1K | |
| 85379 | <1% | 1,402 | $1K | |
| 74174 | <1% | 14 | $909.72 | |
| 80346 | <1% | 48 | $902.14 | |
| 87340 | <1% | 74 | $842.23 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 524 | $811.15 |
| 82550 | <1% | 546 | $789.61 | |
| A9270 | Non-covered item or service | <1% | 12,464 | $753.63 |
| 85018 | <1% | 1,901 | $733.96 | |
| 85007 | <1% | 346 | $683.35 | |
| 00731 | <1% | 451 | $675.54 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,150 | $666.97 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,956 | $650.65 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 63 | $648.37 |
| 86403 | <1% | 978 | $599.98 | |
| 80179 | <1% | 1,494 | $593.08 | |
| 80061 | Lipid panel | <1% | 134 | $591.17 |
| 82435 | <1% | 1,786 | $585.61 | |
| 84132 | <1% | 2,044 | $513.79 | |
| 85730 | <1% | 1,697 | $507.90 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,626 | $506.26 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,375 | $494.05 |
| 87075 | <1% | 1,075 | $471.69 | |
| 80361 | <1% | 48 | $451.02 | |
| 86920 | <1% | 19 | $446.48 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,339 | $403.13 |
| 87077 | <1% | 439 | $401.53 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 502 | $385.72 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 42 | $385.67 |
| 87186 | <1% | 745 | $370.70 | |
| 51798 | <1% | 532 | $364.15 | |
| 84295 | <1% | 1,783 | $350.19 | |
| 00952 | <1% | 17 | $336.12 | |
| 82248 | <1% | 648 | $333.66 | |
| 00811 | <1% | 68 | $327.53 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 397 | $310.07 |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 121 | $285.82 |
| 85652 | <1% | 779 | $284.37 | |
| 87205 | <1% | 331 | $278.47 | |
| 82565 | <1% | 34 | $272.52 | |
| 82247 | <1% | 13 | $250.40 | |
| 87070 | <1% | 259 | $249.22 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 17 | $238.46 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,836 | $234.89 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,359 | $232.97 |
| 99406 | <1% | 19 | $219.24 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,263 | $196.58 |
| A4217 | Sterile water/saline, 500 ml | <1% | 915 | $191.96 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 526 | $160.79 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,265 | $155.11 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 253 | $143.19 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 342 | $139.26 |
| 80329 | <1% | 201 | $130.67 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 315 | $127.29 |
| J7999 | Compounded drug, not otherwise classified | <1% | 686 | $120.33 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,917 | $117.75 |
| 84439 | <1% | 38 | $106.78 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 335 | $103.50 |
| 76937 | <1% | 35 | $101.62 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 18 | $96.59 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 494 | $93.19 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 69 | $90.78 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 276 | $87.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,275 | $84.19 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,575 | $82.73 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,828 | $79.92 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 466 | $73.54 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 511 | $72.35 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 807 | $70.30 |
| 84100 | <1% | 248 | $63.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 218 | $61.99 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 244 | $61.11 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 160 | $58.98 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,118 | $46.23 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 133 | $38.61 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 142 | $37.73 |
| C1769 | Guide wire | <1% | 235 | $34.33 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 392 | $33.90 |
| 83615 | <1% | 65 | $26.36 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,476 | $24.95 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,133 | $22.95 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 252 | $22.79 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,501 | $18.89 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 250 | $15.63 |
| 85014 | <1% | 13 | $15.56 | |
| 85045 | <1% | 45 | $15.41 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 74 | $15.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 182 | $14.90 |
| 82803 | <1% | 12 | $14.47 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 142 | $12.60 |
| 83540 | <1% | 18 | $12.45 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 90 | $10.61 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 180 | $10.61 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 142 | $10.45 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 486 | $7.32 |
| 83550 | <1% | 18 | $6.22 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 406 | $6.09 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 18 | $5.17 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 68 | $3.57 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 564 | $3.06 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 59 | $1.88 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 408 | $0.86 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 150 | $0.63 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 105 | $0.01 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 963 | $0.00 |
| 00400 | 0% | 22 | $0.00 | |
| 0753T | 0% | 92 | $0.00 | |
| 00840 | 0% | 110 | $0.00 | |
| 29125 | 0% | 16 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 30 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 54 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 12 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 63 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 15 | $0.00 |
| 00812 | 0% | 20 | $0.00 | |
| 76377 | 0% | 422 | $0.00 | |
| 94761 | 0% | 440 | $0.00 | |
| 82150 | 0% | 32 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 42 | $0.00 |
| 88342 | 0% | 83 | $0.00 | |
| 94760 | 0% | 229 | $0.00 | |
| 00813 | 0% | 32 | $0.00 | |
| 88304 | 0% | 48 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 26 | $0.00 |
| 86308 | 0% | 13 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 33 | $0.00 |
| 88341 | 0% | 34 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 17 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 26 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 17 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHILLERO, ANTHONY (DIRECTOR, FP&A)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.